KR101772933B1 - Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product - Google Patents
Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product Download PDFInfo
- Publication number
- KR101772933B1 KR101772933B1 KR1020150158589A KR20150158589A KR101772933B1 KR 101772933 B1 KR101772933 B1 KR 101772933B1 KR 1020150158589 A KR1020150158589 A KR 1020150158589A KR 20150158589 A KR20150158589 A KR 20150158589A KR 101772933 B1 KR101772933 B1 KR 101772933B1
- Authority
- KR
- South Korea
- Prior art keywords
- acorn
- liver function
- alcohol
- health functional
- functional composition
- Prior art date
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title claims abstract description 45
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000003908 liver function Effects 0.000 title claims abstract description 30
- 230000002633 protecting effect Effects 0.000 title description 11
- 230000000593 degrading effect Effects 0.000 title 1
- 244000063299 Bacillus subtilis Species 0.000 claims abstract description 13
- 235000014469 Bacillus subtilis Nutrition 0.000 claims abstract description 13
- 230000015556 catabolic process Effects 0.000 claims abstract description 7
- 238000006731 degradation reaction Methods 0.000 claims abstract description 7
- 230000000694 effects Effects 0.000 claims description 41
- 108010021809 Alcohol dehydrogenase Proteins 0.000 claims description 19
- 108010082126 Alanine transaminase Proteins 0.000 claims description 18
- 102000007698 Alcohol dehydrogenase Human genes 0.000 claims description 18
- 102000005369 Aldehyde Dehydrogenase Human genes 0.000 claims description 17
- 108020002663 Aldehyde Dehydrogenase Proteins 0.000 claims description 17
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 14
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 210000004185 liver Anatomy 0.000 claims description 12
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 6
- 229920002079 Ellagic acid Polymers 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 6
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 6
- 229960002852 ellagic acid Drugs 0.000 claims description 6
- 235000004132 ellagic acid Nutrition 0.000 claims description 6
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 6
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 6
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 239000000284 extract Substances 0.000 abstract description 23
- 238000000855 fermentation Methods 0.000 abstract description 16
- 230000004151 fermentation Effects 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 34
- 238000012360 testing method Methods 0.000 description 17
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 14
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 206010019133 Hangover Diseases 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 231100000304 hepatotoxicity Toxicity 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000006872 mrs medium Substances 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 5
- 229960005489 paracetamol Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 206010019851 Hepatotoxicity Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000007686 hepatotoxicity Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000001929 Lactobacillus brevis Species 0.000 description 3
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 241000186840 Lactobacillus fermentum Species 0.000 description 3
- 240000002605 Lactobacillus helveticus Species 0.000 description 3
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000234 hepatic damage Toxicity 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 description 3
- 229940054346 lactobacillus helveticus Drugs 0.000 description 3
- 230000008818 liver damage Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000011511 Diospyros Nutrition 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 241000186610 Lactobacillus sp. Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 244000018633 Prunus armeniaca Species 0.000 description 2
- 235000009827 Prunus armeniaca Nutrition 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012623 in vivo measurement Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102100026605 Aldehyde dehydrogenase, dimeric NADP-preferring Human genes 0.000 description 1
- 102100033816 Aldehyde dehydrogenase, mitochondrial Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001498622 Cixius wagneri Species 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- URNSECGXFRDEDC-UHFFFAOYSA-N N-acetyl-1,4-benzoquinone imine Chemical compound CC(=O)N=C1C=CC(=O)C=C1 URNSECGXFRDEDC-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000007651 Rubus glaucus Species 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- -1 aliphatic halogen hydrocarbon Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000014105 formulated food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000012464 large buffer Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/40—Fermented products; Products treated with microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01001—Alcohol dehydrogenase (1.1.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01003—Aldehyde dehydrogenase (NAD+) (1.2.1.3)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
-
- A23Y2220/67—
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a health functional composition for alcohol degradation and liver function protection containing an acorn fermented product. More particularly, the present invention relates to a health functional composition for alcohol degradation and hepatic function protection containing fermented product obtained by fermentation with Bacillus subtilis extract obtained by extracting 70% ethanol with acorn as a raw material.
Description
The present invention relates to a health functional composition for alcohol degradation and liver function protection containing an acorn fermented product. More particularly, the present invention relates to a health functional composition for alcohol degradation and hepatic function protection containing fermented product obtained by fermentation with Bacillus subtilis extract obtained by extracting 70% ethanol with acorn as a raw material.
Acorn is a generic term for oak, oak, oak, oak, etc. In Korea, acorn has been used as a starch for cooking. Acorns are nutritious foods because they contain large amounts of protein, carbohydrates and fats as well as high levels of vitamins such as calcium, phosphorus, potassium and niacin.
Galactic acid, diglycic acid, and galantannin contained in acorns are known as antioxidants. When acorn powder is extracted with water, the antioxidant effect is improved, suggesting its utility as a traditional food or a functional food material.
When acorn powder was administered to mice that induced memory learning disorders, the synthesis of acetylcholine (Ach), a catecholamine substance, as a major neurotransmitter in the brain was increased, and inhibition of acetylcholinesterase activity and catecholamine- In this study, we investigated the effects of acorn powder on the dementia of the elderly patients with acute dementia (Lee, SH, et al., 2005). (5) 738-742).
Meanwhile, Korean Patent Registration No. 10-567564 'Method of extracting active ingredient of acorn and drink containing extract of active ingredient of acorn', a method of extracting an obesity controlling substance as an active ingredient of acorn and a drink containing the extract are presented have.
Meanwhile, the liver is an important organ for blood storage and circulatory detoxification in the human body. As our body is exposed to various pollutants and toxic substances, the liver is overloaded, and furthermore, mental stress, drinking and smoking are causing serious liver damage. The liver is an organ with a large buffer capacity. The symptoms are not visible in the early stage of the disease and the disease is not detected until it gets worse.
Generally, hepatotoxicity inducers include carbon tetrachloride, acetaminophen, etc. The carbon tetrachloride, which is an aliphatic halogen hydrocarbon, causes damage to the biomembrane and causes toxic effects on liver and kidney. Excess acetaminophen is caused by NAPQI It is known to bind to glutathione after conversion to lower liver function.
In recent years, foods or medicines derived from natural products have been developed and used for preventing or treating such liver toxicity.
Korean Patent Laid-Open Publication No. 10-2002-81995 discloses an agent for improving hangover and a liver function by the formulated food product and a method for producing the same, which comprises one or two kinds of persimmon shells, parsley, persimmons, omija, mung bean, A compounded food having an effect of eliminating a hangover and improving liver function using an extract obtained by differentiating the mixture with a raw material of a certain kind or more as an effective ingredient is disclosed.
Korean Patent Laid-Open Publication No. 10-2002-64151 'A low alcohol-insoluble extract fraction and polysaccharide material having a hepatic toxicity and a hangover resolution activity isolated from a hinoki tree and a composition containing the same " A low alcohol-insoluble extract fraction having activity, a polysaccharide substance and a composition containing the same.
Korean Patent Laid-Open Publication No. 10-2012-52614 discloses a composition for improving liver function and a food for hangover, which comprises a herbal medicine extract in a composition for improving liver function and extracting hangover from a herbal medicine extract, , Which is an effective component of the extract, which is extracted from a mixture of a plant material, a planthopper, an apricot, an apricot, an acorn, a bamboo shoot, an orioma, ≪ / RTI >
In addition, the food composition disclosed in the above patent document is safe using herbal medicines, and the herbal medicine extract mixed at a specific ratio induces a synergistic effect of the hepatic function improving effect, thereby demonstrating excellent liver function improvement and hangover relieving effect.
The present inventors selected acorns from among the herbal medicines that are expected to be effective for the prevention or treatment of liver toxicity clinically, and fermented the extract of acorn fruit to improve the liver function, rapidly dissolve ethanol, The present inventors have completed the present invention by developing a health functional composition for protecting liver function.
The object of the present invention is to select acorns and to ferment acorn fruits from herbal medicines which are expected to be effective for prevention or treatment of hepatotoxicity, thereby improving liver function, rapid ethanol decomposition and acorn fermentation And to develop a health functional composition for protecting the liver function.
It is an object of the present invention to provide a health functional composition having an alcohol decomposition and liver function protecting effect containing an acorn fermented product obtained by fermenting 70% ethanol extract of acorn as an active ingredient.
At this time, the acorn fermented product is characterized by fermenting acorn extract with 70% ethanol as Bacillus subtilis or Lactobacillus plantarum.
In addition, the alcohol degradation effect is characterized by enhancing the enzymatic activity of the alcohol dehydrogenase (ADH) and the aldehyde dehydrogenase (ALDH) in the body.
On the other hand, the liver function protection effect is to lower the AST (SGOT), ALT (SGPT) and LDH levels in the blood.
Also, the health functional composition comprises 0.1 to 10.0% by weight of Ellagic acid as an indicator component.
The effect of the present invention is that acorns are selected from among herbal medicines which are expected to be effective for prevention or treatment of hepatotoxicity and fermented with an extract of acorn fruit to improve the liver function, And a health functional composition for protecting liver function.
1 is a graph showing ADH activity of each sample measured in Example 1 of the present invention.
2 is a graph showing ALDH activity for each sample measured in Example 2 of the present invention.
FIG. 3 shows the blood alcohol content in the mouse between the administration group of Bacillus subtilis fermented product and the control group measured in Example 3 of the present invention.
4 is a graph showing the AST, ALT and LDH contents among the control group, the control test group and the test group measured in Example 4 of the present invention.
The present invention relates to a health functional composition comprising an acorn fermented product obtained by fermenting 70% ethanol extract of acorn as an active ingredient and having an alcohol decomposition and liver function protecting effect.
Also, the acorn fermented product is obtained by fermenting 70% ethanol extract of acorn with Bacillus subtilis or Lactobacillus plantarum. .
In addition, the alcohololysis effect enhances the enzymatic activity of the alcohol dehydrogenase (ADH) and the aldehyde dehydrogenase (ALDH) in the body.
On the other hand, the liver function protection effect is to lower the AST (SGOT), ALT (SGPT) and LDH levels in the blood.
Also, the health functional composition comprises 0.1 to 10.0% by weight of Ellagic acid as an indicator component.
Hereinafter, the present invention will be described in more detail.
Alcohol dehydrogenase (ADH) is an enzyme belonging to the enzyme class EC 1.1.1.1 and is an enzyme that reversibly catalyzes the formation of aldehyde or ketone by dehydrogenation of alcohol. It is also capable of acting on other alcohols with a wide range of substrate specificities.
The aldehyde dehydrogenase (ALDH) can catalyze the reverse reaction as an enzyme that oxidizes an aldehyde to produce a carboxylic acid or an acyl group. Liver enzymes mainly produce acetic acid in acetaldehyde and coenzyme NAD (EC 1.2.1.3) or NADP (EC 1.2.1.4) and belong to the enzyme class EC 1.2.1.5.
Therefore, in the case of the health functional composition for protecting liver function of the present invention, the enzymatic activity of the in vivo alcohol dehydrogenase and the aldehyde dehydrogenase is increased, so that the ethanol is rapidly decomposed in the body and the hangover is eliminated.
Aspartate aminotransferase (AST) is present in the form of several isoenzymes in hepatocytes and muscle cells. When it is destroyed by various diseases, it flows out to the blood and increases. It is important to diagnose myocardial infarction and increase in liver disease. Diagnosis and treatment of liver disease and bone disease are helpful in determining the effectiveness of treatment. If a tumor develops in the bile duct or obstructs the bile duct, the cells of the bile duct are broken and the blood alkaline phosphatase is increased.
Alanine transaminase (ALT) belongs to the enzyme class EC 2.6.1.2, which is mainly present in liver and plasma. ALT is an enzyme that transfers amino group from L-alanine to α-ketoglutarate and is used as an index to diagnose the degree of liver damage.
The health functional composition comprising the acorn fermented product obtained by fermenting the 70% ethanol extract of acorn of the present invention as an active ingredient contains 0.1 to 10.0% by weight of Ellagic acid as an index component.
Elagic acid consists of four rings of polyphenols and is present in the plant in the form of ellagitannin, a precursor. Grape, strawberry, pomegranate, raspberry, peanut and green tea, and has antioxidant, antiviral, antimutagenic and anticancer functions.
It has been reported to inhibit cancer cell activity in breast and esophagus, skin, colon, prostate and pancreas. It has also been shown to reduce the toxicity of carbon tetrachloride, which induces fibrosis in the liver of rat rats administered orally.
Accordingly, the health functional composition for protecting liver function of the present invention shows a protective effect of the liver function in vivo, thereby lowering the levels of serum AST and ALT, which are indicators of the degree of liver damage.
The health functional composition for protecting liver function of the present invention may further comprise suitable carriers, excipients and diluents conventionally used. When the health functional composition of the present invention is formulated into a medicinal composition for protecting liver function, it may contain 0.1 to 70% by weight of an acorn fermented product.
In addition, the health functional composition of the present invention may be administered by various routes and may be administered by parenteral routes such as oral administration, subcutaneous injection of muscle, and rectal administration.
In addition, the health functional composition for protecting liver function of the present invention can be formulated into various forms of foods and can be formulated into foods or beverages such as beverages, gums, tea, etc. in addition to ordinary tablets, capsules, pills, . In addition, ordinary fillers, extenders, binders, wetting agents, disintegrants, surfactants, diluents, excipients and the like can be added in the formulation.
Hereinafter, the present invention will be described in more detail with reference to Production Examples and Examples.
(Production Example 1) Preparation of acorn extract
1.2 kg of acorn, which is oak berries, was added, and 2,000 ml of 70% ethanol was added and extracted with heat. The extract was filtered, and the filtrate was concentrated using a rotary evaporator. The obtained crude extract was dried with a freeze dryer to prepare a powder. The yield was 120.5 g (10%).
(Production Example 2) Production of acorn fermentation product using Bacillus subtilis (5% glucose agar medium)
First, 1 ml of freeze-dried Bacillus subtilis suspension is placed in about 10 ml of agar medium and cultured at 30 ° C for 24 hours. 0.1 ml of this primary culture is taken and secondary cultured using 10 ml of agar medium. When the culture solution is measured at 400 nm, the absorbance of the spectrophotometer is between 2 and 3. 30 ml of the agar medium is added to 1 ml of the culture medium, and the absorbance is adjusted to 0.2 to prepare 30 ml of the culture medium.
The composition of the agar medium used herein was 3.0 g of beef extract, 5.0 g of peptone, 15.0 g of agar, 1.0 L of distilled water (pH 6.8), 5 wt% of glucose, and 0.5 wt% of yeast extract.
3 g of each acorn extract prepared in Preparation Example 1 is added to 30 ml of the above culture (10%) and cultured at 30 ° C for 24 hours. Next, the culture solution was sterilized at high pressure and high temperature and then concentrated using a vacuum evaporator to obtain a powdery extract.
(Production Example 3) Production of acorn fermented product using Lactobacillus sp. (MRS medium)
Lactobacillus plantarum subsprisa planta lum (Accession No .: KCTC-3108) was cultured in the same manner as in Example 2 except that the medium was in an MRS medium at 37 ° C. Powdery extracts obtained by concentration using a decompression evaporator were used in the experiments.
The composition of the MRS medium used was 10.0 g of peptone, 10.0 g of beef extract, 5.0 g of yeast extract, 20.0 g of glucose, 1.0 ml of
(Production Example 4) Production of acorn fermentation product using Lactobacillus sp. (MRS medium)
The stock solution (10 ml) was inoculated with 1 × 10 8 cfu / ml of 5 Lactobacillus strains to inoculate the above MRS medium so that the lactic acid bacteria solution was 0.2% (v / v). The culture was incubated at 37 ° C for 7 days. 3 g of the acorn extract prepared in Preparation Example 1 is added to 600 ml of MRS medium. The culture was centrifuged at 1,000 × g for 10 minutes at 4 ° C., and the supernatant was separated and concentrated using a vacuum evaporator to obtain a powdery extract.
Lactobacillus casei (Accession No .: KCTC-3109), Lactobacillus fermentum (Accession No .: KCTC-3112), Lactobacillus brevis (Accession No .: KCTC-3498), Lactobacillus helveticus (Accession No .: KCTC-3545), Lactobacillus delbrueckii subsp. bulgaricus (Accession No .: KCTC-3635)
(Example 1) Measurement of the effect of alcohol dehydrogenase (ADH) activity
ADH activity was measured by measuring the absorbance of NADH to NADH using a UV spectrophotometer. The concentration of the sample used in the examples was 5 mg / ml.
A reaction solution consisting of 0.38 ml of 1 M Tris-hydrochloric acid buffer (pH 8.0), 0.7 ml of distilled water, 0.15 ml of 20 mM NAD, 0.15 ml of 0.2 M ethanol and 50 μl of a sample (5 mg / ml) (5 units / ml) was added, and the reaction was allowed to proceed at 25 ° C for 5 minutes. Then, an increase in absorbance was measured at 340 nm. The ADH activity was expressed as a ratio of the maximum absorbance at the end of the reaction to the maximum absorbance of the control, and was calculated by the following equation.
ADH activity = (B / A) x 100
A: maximum absorbance of the control, B: maximum absorbance of the experimental group
As shown in FIG. 1, the ADH activity in the sample was highest in the Bacillus subtilis fermented product of
(Example 2) Measurement of effect of aldehyde dehydrogenase (ALDH) activity
The activity of ALDH activity was measured by measuring the absorbance of NADH to NADH using a UV spectrophotometer. The concentration of the sample was 5 mg / ml.
0.15 ml of 1 M Tris-hydrochloric acid buffer solution (pH 8.0), 1.05 ml of distilled water, 50 μl of 20 mM NAD, 50 μl of 0.1 M acetaldehyde, 50 μl of 3.0 M KCl, 50 μl of 0.33 M BME and 50 μl of a sample The reaction mixture was preincubated at 25 ° C for 10 minutes, reacted at 25 ° C for 5 minutes with 50 μl of ALDH (1 Unit / ml), and the absorbance was measured at 340 nm. ALDH activity was expressed as the ratio of the maximum absorbance at the end of the reaction to the maximum absorbance of the control, and was calculated by the following equation.
ALDH activity = (B / A) x 100
A: maximum absorbance of the control, B: maximum absorbance of the experimental group
As shown in FIG. 2, the ALDH activity in the sample was highest in the Bacillus subtilis fermented product of the
(Example 3) Alcohol content In vivo measurement test
Experimental animals were divided into a test group and a control group by taking
The results of measuring the content of alcohol in the blood after administering the fermented Bacillus subtilis with the highest activity of the alcohololytic enzymes to the experimental animals are shown in FIG. As shown in FIG. 3, the alcohol content of the control group to which the fermented product was not administered was 0.0515%, but the alcohol content of the test group administered with the fermented product was 0.01443%, and the blood alcohol content in the mouse was 72% lower .
(Example 4) Liver protective effect In vivo measurement test (AST, ALT, LDH)
Seven experimental animals were divided into a control group, a test group and a control test group. Experimental animals were experimented after being purified for one week after purchase. In the control group, neither acetaminophen (APAP) nor the test samples of the present invention were administered. In the test group, acetaminophen (APAP) was orally administered in DMSO at a concentration of 350 mg / kg. After 3 days, one more dose of APAP was administered. One hour after administration, the test sample was orally administered at a concentration of 1,000 mg / kg. Samples were orally administered at the same time for 6 days. In the control group, acetaminophen (APAP) was orally administered in DMSO at a concentration of 350 mg / kg. Three days later, APAP was administered once more.
After 24 hours of oral administration of the test sample, blood was collected from the liver, the test group, and the control group. The serum was separated by centrifugation (3,000 rpm, 5 minutes) ALT (SGPT) and LDH contents were analyzed.
As shown in FIG. 4, AST, ALT and LDH activities were greatly increased in the control test group that caused hepatotoxicity, but the AST activity and the ALT activity of the fermented test group were 33.8% 38.5% and LDH activity was reduced by 13.9%. This proves that the sample of the present invention has an effect of reducing the AST (SGOT), ALT (SGPT) and LDH levels in the blood, thereby improving the toxicity of the liver.
(Example 5) Identification of eragacic acid component of acorn fermented product
1 mg of the acorn fermented product using the Bacillus subtilis prepared in Preparation Example 2 was dissolved in 1 ml of methanol and used as a sample for HPLC analysis. The HPLC analysis conditions are as follows.
- HPLC: Agilent 1260 infinity
- Column: YMC triart C18 (250 mm x 4.6 mm, 5 탆, 120 Å)
- Injection volume: 5 μl
- Detection wavelength: 254 nm
- mobile phase: A- 0.1% TFA (water)
B-0.1% TFA (acetonitrile)
The obtained HPLC detection peak was compared with the detection peak of the elagancy standard solution to confirm that the maximum peak of the acorn fermentation of the present invention was elagic acid.
On the other hand, quantitative analysis of the content of ellagic acid showed that about 17.2 ± 0.13 μg of ellagic acid was present in 1 ml of the sample. Therefore, it was confirmed that the content of elastase in the acorn fermented product using the Bacillus subtilis prepared in Preparation Example 2 was about 1.7% by weight.
Claims (5)
The alcohol degradation effect enhances the enzymatic activity of the alcohol dehydrogenase (ADH) and the aldehyde dehydrogenase (ALDH) in the body
Wherein the liver function protection effect is a decrease in AST (SGOT), ALT (SGPT) and LDH levels in the blood.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150158589A KR101772933B1 (en) | 2015-11-12 | 2015-11-12 | Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150158589A KR101772933B1 (en) | 2015-11-12 | 2015-11-12 | Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170055660A KR20170055660A (en) | 2017-05-22 |
| KR101772933B1 true KR101772933B1 (en) | 2017-08-30 |
Family
ID=59050022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150158589A KR101772933B1 (en) | 2015-11-12 | 2015-11-12 | Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101772933B1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102138715B1 (en) * | 2017-12-11 | 2020-08-05 | 주식회사 네이처프럼 | Fermented beverage drink using Paraburkholderia and method for producing the same |
| CN111548947A (en) * | 2019-06-06 | 2020-08-18 | 郑州大学 | Lactic acid bacteria product and its sobering-up use |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100718343B1 (en) * | 2005-12-07 | 2007-05-14 | 씨제이푸드빌 주식회사 | Jelly produced by using acorn and a method for production thereof |
| KR101121570B1 (en) * | 2010-11-11 | 2012-03-06 | 동국대학교 경주캠퍼스 산학협력단 | Fermentation method of starfish extract using microorganisms and hangover curing agent comprising starfish extract fermented by the same |
| KR101470888B1 (en) * | 2013-12-24 | 2014-12-15 | 재단법인춘천바이오산업진흥원 | Composition for liver protection containing the fermented extract of Ligularia fischeri |
-
2015
- 2015-11-12 KR KR1020150158589A patent/KR101772933B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100718343B1 (en) * | 2005-12-07 | 2007-05-14 | 씨제이푸드빌 주식회사 | Jelly produced by using acorn and a method for production thereof |
| KR101121570B1 (en) * | 2010-11-11 | 2012-03-06 | 동국대학교 경주캠퍼스 산학협력단 | Fermentation method of starfish extract using microorganisms and hangover curing agent comprising starfish extract fermented by the same |
| KR101470888B1 (en) * | 2013-12-24 | 2014-12-15 | 재단법인춘천바이오산업진흥원 | Composition for liver protection containing the fermented extract of Ligularia fischeri |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170055660A (en) | 2017-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | Enhancement of the antioxidant capacity of soy whey by fermentation with Lactobacillus plantarum B1–6 | |
| JP5162212B2 (en) | Novel lactic acid bacteria, lactic acid bacteria composition and plant extract, and method for producing plant extract and low molecular weight polyphenol | |
| KR101925096B1 (en) | A manufacturing method of hangover-eliminating enzyme powder and a composition for relieving hangover comprising thereof | |
| KR100716133B1 (en) | Health-improving garlic ingredient having reduced pungent flavor and method for the preparation thereof | |
| KR101930483B1 (en) | Smilax china leaf fermented with Aspergillus species and Extract of the same | |
| KR101811034B1 (en) | COMPOSITION FOR WHITENING CONTAINING Fermented Castanea crenata inner shell extracts | |
| KR101720051B1 (en) | Pharmaceutical composition comprising fermented Aralia cordata Thunb for preventing or treating arthritis | |
| Kim et al. | Preparation and characterization of fermented dandelion (Taraxacum officinale) beverage using Lactobacillus acidophilus F46 having cinnamoyl esterase activity | |
| KR101772933B1 (en) | Health functional composition for degrading alcohol and protecting liver function containing acorn fermenting product | |
| KR101091833B1 (en) | Methods for preparing high quantity of S-allyl-L-cysteine to fermented products of garlic using lactic acid bacteria | |
| AU2019416609B2 (en) | Kimchi for preventing or treating helicobacter pylori-associated diseases | |
| KR101510673B1 (en) | Composition inhibiting enterobacteria activity during saponin metabolism of ginseng | |
| KR102438276B1 (en) | Anti-inflammatory and anti-obesity composition comprising Sargassum horneri extract and method for preparing the same | |
| KR20090043758A (en) | Composition for improvement of fatty liver | |
| KR101608502B1 (en) | Composition for prevention or treatment of cardiovascular diseases comprising fermentation product of garlic | |
| KR101249800B1 (en) | Extract of red bean fermented with monascus species, method for preparing the same and use of the same | |
| KR101399398B1 (en) | Method for manufacturing submerged-state fermented Allium victorialis and Composition for preventing or treating anti-diabetes or anti-diabetic complication containing fermented Allium victorialis | |
| KR20160082824A (en) | Composition for Preventing Obesity and Improving Lipid Metabolism Using Active Ingredient with the Mixture of Extract of Rubus Occidentalis and Red Ginseng Fermentation | |
| CN112423770A (en) | Composition for improving diabetes or enhancing antioxidant activity comprising yeast extract and method for preparing yeast extract | |
| KR102580158B1 (en) | Composition for preventing, improving or treating osteoporosis comprising fermented Aurea helianthus using Bacillus genus strain | |
| KR101376629B1 (en) | New Lactobacillus arizonensis BCNU 9200 and probiotics composition comprising the same | |
| KR20100090985A (en) | Composition for treating or preventing intestinal disorders | |
| JP2010285353A (en) | Growth inhibitor of helicobacter pylori and method for producing the same | |
| KR20170120269A (en) | A method of preparing fermented hizikia fusiformis having anti-inflammatory | |
| JP5892488B2 (en) | New lactic acid bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |